title: Duration and extent of antianginal effects of a sustained-release formulation of nifedipine in angina.
abstract: Twenty-four patients with chronic stable exertional angina pectoris were randomized in a double-blind, placebo-controlled, crossover trial to assess the efficacy and durability of a newly developed, sustained-release formulation of nifedipine (nifedipine CC) in a single 40-mg oral dose. Symptom-limited graded treadmill exercise tests were performed just before, and at 4, 7, and 24 h after a single administration of the drug or the placebo was given. Exercise tolerance at 4, 7, and 24 h after the drug were compared with the corresponding placebo values. Data could be analysed for 19 patients. Maximal exercise time, time to the onset of angina, and time to 1 mm ST segment placebo. The average maximal exercise time was significantly increased by 72, 76, and 37 s at 4, 7, and 24 h. Rate-pressure product at rest and at peak exercise showed significant changes only at 24 h compared with placebo (both P < 0.05). The maximal increase in exercise tolerance was most marked at 7 h nifedipine CC, at which time plasma drug concentration was 99.4 +/- 14.0 ng.ml-1. Thus, in patients with chronic stable exertional angina pectoris, nifedipine CC showed a prolonged improvement in exercise tolerance up to 24 h after a single oral administration.
authors.affiliation: Department of Clinical Laboratory Medicine, Nagoya University Hospital, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yokota
authors.forename: F
authors.initials: F
authors.lastname: Saito
authors.forename: H
authors.initials: H
authors.lastname: Izawa
authors.forename: T
authors.initials: T
authors.lastname: Matsunami
authors.forename: J
authors.initials: J
authors.lastname: Yoshida
authors.forename: H
authors.initials: H
authors.lastname: Inagaki
authors.forename: I
authors.initials: I
authors.lastname: Sotobata
mesh_terms: D000787:Angina Pectoris / Q000503:physiopathology / Q000517:prevention & control*; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005080:Exercise Test; D017079:Exercise Tolerance / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D003692:Delayed-Action Preparations; D009543:Nifedipine